Drug makers claim high prices are necessary to support new drug development and innovation, but research shows that public investment in drug research and development combined with large industry profits leaves manufacturers room to lower prices while continuing to innovate.
Author Archive for: sarah-lanford
About Sarah Lanford
Sarah Lanford joined NASHP in August 2018. As a policy associate, she works with the Emerging Policy Issues team, and projects related to prescription drug costs. Before joining NASHP, Sarah worked at Stateside Associates, where she monitored and analyzed state health policy legislation. She has also worked for the Texas Democratic Party and the Texas State Senate, and served as a page in the United States Senate. She holds a BA in government from the University of Texas at Austin.
Entries by Sarah Lanford
Last month, Winter Storm Uri caused catastrophic power outages across Texas. National Academy for State Health Policy staff Eskedar Girmash and Sarah Lanford, who work remotely from Dallas and Houston during the pandemic, were both without power for four days as temperatures fell to single digits and they lost access to water. At least 58 people died trying to stay warm, and more […]
Today, the US Supreme Court is scheduled to hear oral arguments in a legal challenge of an Arkansas law that regulates the reimbursement rates that pharmacy benefit managers (PBMs) pay to pharmacies.
At least 11 states have acted to limit the dispensing of chloroquine and hydroxychloroquine – prescription drugs that have been cited as providing protection against coronavirus (COVID-19) without adequate clinical evidence to support that claim. To protect consumers with or at risk of COVID-19 and to prevent stockpiling of these drugs, which treat malaria, rheumatoid […]
In their 2020 state of the state speeches, governors identified new health policy initiatives on a wide range of issues. As of mid-February, 42 governors had delivered speeches or outlined key budget priorities, and all addressed health issues – most commonly strategies to tackle health care costs and behavioral health issues. Below are highlights of the key health themes […]
Last week, California enacted the first-in-the-nation state law to combat pay-for-delay deals between brand-name and generic pharmaceutical drug manufacturers. In a pay-for-delay deal, a brand manufacturer pays a generic competitor to settle patent litigation and keep the lower-cost version of the drug off the market. Delaying market entry of generic drugs limits competition and can […]